Bacillus anthracis edema factor substrate specificity: Evidence for new modes of action

Toxins

Volumn 4, Issue 7, 2012, Pages 505-535

  Göttle, Martin ^a   Dove, Stefan ^b   Seifert, Roland ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Adenylyl cyclase toxin; Anthrax; Bacillus anthracis; Edema factor; Edema toxin

Indexed keywords

ADENYLATE CYCLASE; BACTERIAL TOXIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC CMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC IMP; CYCLIC NUCLEOTIDE GATED CHANNEL; CYCLIC UMP; CYTIDINE TRIPHOSPHATE; EDEMA FACTOR; INOSINE TRIPHOSPHATE; PHOSPHODIESTERASE; UNCLASSIFIED DRUG; URIDINE TRIPHOSPHATE;

BACILLUS ANTHRACIS; CELL FUNCTION; CYCLIZATION; ENZYME ACTIVITY; ENZYME SPECIFICITY; HOST RESISTANCE; HUMAN; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ADENYLATE CYCLASE; ANIMALS; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; CATALYTIC DOMAIN; EXOTOXINS; HUMANS; MODELS, MOLECULAR; NUCLEOTIDES, CYCLIC; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY; URIDINE MONOPHOSPHATE;

BACILLUS ANTHRACIS;

EID: 84864364923     PISSN: 20726651     EISSN: None     Source Type: Journal    
DOI: 10.3390/toxins4070505     Document Type: Review

References (211)

1. Mosenden, R.; Tasken, K. Cyclic AMP-mediated immune regulation-overview of mechanisms of action in T cells. Cell. Signal. 2011, 23, 1009-1016.
2. Defer, N.; Best-Belpomme, M.; Hanoune, J. Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. Am. J. Physiol. Renal Physiol. 2000, 279, F400-F416.
3. Sadana, R.; Dessauer, C.W. Physiological roles for G protein-regulated adenylyl cyclase isoforms: Insights from knockout and overexpression studies. Neurosignals 2009, 17, 5-22.
4. Chen, J.; Levin, L.R.; Buck, J. Role of soluble adenylyl cyclase in the heart. Am. J. Physiol. Heart Circ. Physiol. 2012, 302, H538-543.
5. Hanoune, J.; Defer, N. Regulation and role of adenylyl cyclase isoforms. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 145-174.
6. Hanoune, J.; Pouille, Y.; Tzavara, E.; Shen, T.; Lipskaya, L.; Miyamoto, N.; Suzuki, Y.; Defer, N. Adenylyl cyclases: Structure, regulation and function in an enzyme superfamily. Mol. Cell. Endocrinol. 1997, 128, 179-194.
7. Patel, T.B.; Du, Z.; Pierre, S.; Cartin, L.; Scholich, K. Molecular biological approaches to unravel adenylyl cyclase signaling and function. Gene 2001, 269, 13-25.
8. Shirshev, S.V. Role of Epac proteins in mechanisms of cAMP-dependent immunoregulation. Biochemistry (Moscow) 2011, 76, 981-998.
9. Breckler, M.; Berthouze, M.; Laurent, A.C.; Crozatier, B.; Morel, E.; Lezoualc'h, F. Rap-linked cAMP signaling Epac proteins: compartmentation, functioning and disease implications. Cell. Signal. 2011, 23, 1257-1266.
10. Laurent, A.C.; Breckler, M.; Berthouze, M.; Lezoualc'h, F. Role of Epac in brain and heart. Biochem. Soc. Trans. 2012, 40, 51-57.
11. Kleppe, R.; Krakstad, C.; Selheim, F.; Kopperud, R.; Doskeland, S.O. The cAMP-dependent protein kinase pathway as therapeutic target: Possibilities and pitfalls. Curr. Top. Med. Chem. 2011, 11, 1393-1405.
12. Göttle, M.; Geduhn, J.; König, B.; Gille, A.; Höcherl, K.; Seifert, R. Characterization of mouse heart adenylyl cyclase. J. Pharmacol. Exp. Ther. 2009, 329, 1156-1165.
13. Stangherlin, A.; Zaccolo, M. CGMP-CAMP interplay in cardiac myocytes: A local affair with far-reaching consequences for heart function. Biochem. Soc. Trans. 2012, 40, 11-14.
14. Morgado, M.; Cairrao, E.; Santos-Silva, A.J.; Verde, I. Cyclic nucleotide-dependent relaxation pathways in vascular smooth muscle. Cell. Mol. Life Sci. 2012, 69, 247-266.
15. Potter, L.R. Guanylyl cyclase structure, function and regulation. Cell. Signal. 2011, 23, 1921-1926.
16. Hammond, J.; Balligand, J.L. Nitric oxide synthase and cyclic GMP signaling in cardiac myocytes: From contractility to remodeling. J. Mol. Cell. Cardiol. 2012, 52, 330-340.
17. Francis, S.H.; Blount, M.A.; Corbin, J.D. Mammalian cyclic nucleotide phosphodiesterases: Molecular mechanisms and physiological functions. Physiol. Rev. 2011, 91, 651-690.
18. Russel, F.G.; Koenderink, J.B.; Masereeuw, R. Multidrug resistance protein 4 (MRP4/ABCC4): A versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol. Sci. 2008, 29, 200-207.
19. Copsel, S.; Garcia, C.; Diez, F.; Vermeulem, M.; Baldi, A.; Bianciotti, L.G.; Russel, F.G.; Shayo, C.; Davio, C. Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation. J. Biol. Chem. 2011, 286, 6979-6988.
20. Ravna, A.W.; Sylte, I.; Sager, G. A molecular model of a putative substrate releasing conformation of multidrug resistance protein 5 (MRP5). Eur. J. Med. Chem. 2008, 43, 2557-2567.
21. McDonough, K.A.; Rodriguez, A. The myriad roles of cyclic AMP in microbial pathogens: From signal to sword. Nat. Rev. Microbiol. 2012, 10, 27-38.
22. Vojtova, J.; Kamanova, J.; Sebo, P. Bordetella adenylate cyclase toxin: A swift saboteur of host defense. Curr. Opin. Microbiol. 2006, 9, 69-75.
23. Ahuja, N.; Kumar, P.; Bhatnagar, R. The adenylate cyclase toxins. Crit. Rev. Microbiol. 2004, 30, 187-196.
24. Carbonetti, N.H.; Artamonova, G.V.; Andreasen, C.; Bushar, N. Pertussis toxin and adenylate cyclase toxin provide a one-two punch for establishment of Bordetella pertussis infection of the respiratory tract. Infect. Immun. 2005, 73, 2698-2703.
25. Carbonetti, N.H.; Artamonova, G.V.; Mays, R.M.; Worthington, Z.E. Pertussis toxin plays an early role in respiratory tract colonization by Bordetella pertussis. Infect. Immun. 2003, 71, 6358-6366.
26. Abramowitz, J.; Campbell, A.R. Cholera toxin action on rabbit corpus luteum membranes: Effects on adenylyl cyclase activity and adenosine diphospho-ribosylation of the stimulatory guanine nucleotide-binding regulatory component. Biol. Reprod. 1985, 32, 463-474.
27. Ivarsson, M.E.; Leroux, J.C.; Castagner, B. Targeting bacterial toxins. Angew. Chem. Int. Ed. Engl. 2012, 51, 4024-4045.
28. Tang, W.J.; Guo, Q. The adenylyl cyclase activity of anthrax edema factor. Mol. Aspects Med. 2009, 30, 423-430.
29. Tournier, J.N.; Rossi Paccani, S.; Quesnel-Hellmann, A.; Baldari, C.T. Anthrax toxins: A weapon to systematically dismantle the host immune defenses. Mol. Aspects Med. 2009, 30, 456-466.
30. Rossi Paccani, S.; Benagiano, M.; Capitani, N.; Zornetta, I.; Ladant, D.; Montecucco, C.; D'Elios, M.M.; Baldari, C.T. The adenylate cyclase toxins of Bacillus anthracis and Bordetella pertussis promote Th2 cell development by shaping T cell antigen receptor signaling. PLoS Pathog. 2009, 5, e1000325.
31. Bauche, C.; Chenal, A.; Knapp, O.; Bodenreider, C.; Benz, R.; Chaffotte, A.; Ladant, D. Structural and functional characterization of an essential RTX subdomain of Bordetella pertussis adenylate cyclase toxin. J. Biol. Chem. 2006, 281, 16914-16926.
32. Guermonprez, P.; Khelef, N.; Blouin, E.; Rieu, P.; Ricciardi-Castagnoli, P.; Guiso, N.; Ladant, D.; Leclerc, C. The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M)beta(2) integrin (CD11b/CD18). J. Exp. Med. 2001, 193, 1035-1044.
33. Carbonetti, N.H. Pertussis toxin and adenylate cyclase toxin: Key virulence factors of Bordetella pertussis and cell biology tools. Future Microbiol. 2010, 5, 455-469.
34. Basler, M.; Masin, J.; Osicka, R.; Sebo, P. Pore-forming and enzymatic activities of Bordetella pertussis adenylate cyclase toxin synergize in promoting lysis of monocytes. Infect. Immun. 2006, 74, 2207-2214.
35. Boyd, A.P.; Ross, P.J.; Conroy, H.; Mahon, N.; Lavelle, E.C.; Mills, K.H. Bordetella pertussis adenylate cyclase toxin modulates innate and adaptive immune responses: Distinct roles for acylation and enzymatic activity in immunomodulation and cell death. J. Immunol. 2005, 175, 730-738.
36. Hritonenko, V.; Mun, J.J.; Tam, C.; Simon, N.C.; Barbieri, J.T.; Evans, D.J.; Fleiszig, S.M. Adenylate cyclase activity of Pseudomonas aeruginosa ExoY can mediate bleb-niche formation in epithelial cells and contributes to virulence. Microb. Pathog. 2011, 51, 305-312.
37. Mock, M.; Fouet, A. Anthrax. Annu. Rev. Microbiol. 2001, 55, 647-671.
38. Mourez, M.; Lacy, D.B.; Cunningham, K.; Legmann, R.; Sellman, B.R.; Mogridge, J.; Collier, R.J. 2001: A year of major advances in anthrax toxin research. Trends Microbiol. 2002, 10, 287-293.
39. Oncu, S.; Oncu, S.; Sakarya, S. Anthrax-An overview. Med. Sci. Monit. 2003, 9, RA276-283.
40. Hicks, C.W.; Sweeney, D.A.; Cui, X.; Li, Y.; Eichacker, P.Q. An overview of anthrax infection including the recently identified form of disease in injection drug users. Intensive Care Med. 2012, 38, 1092-1104.
41. Sweeney, D.A.; Hicks, C.W.; Cui, X.; Li, Y.; Eichacker, P.Q. Anthrax infection. Am. J. Respir. Crit. Care Med. 2011, 184, 1333-1341.
42. Young, J.A.; Collier, R.J. Anthrax toxin: Receptor binding, internalization, pore formation, and translocation. Annu. Rev. Biochem. 2007, 76, 243-265.
43. Guichard, A.; Nizet, V.; Bier, E. New insights into the biological effects of anthrax toxins: Linking cellular to organismal responses. Microbes Infect. 2012, 14, 97-118.
44. Bann, J.G. Anthrax toxin protective antigen-insights into molecular switching from prepore to pore. Protein Sci. 2012, 21, 1-12.
45. Feld, G.K.; Kintzer, A.F.; Tang, I.I.; Thoren, K.L.; Krantz, B.A. Domain flexibility modulates the heterogeneous assembly mechanism of anthrax toxin protective antigen. J. Mol. Biol. 2012, 415, 159-174.
46. Feld, G.K.; Thoren, K.L.; Kintzer, A.F.; Sterling, H.J.; Tang, I.I.; Greenberg, S.G.; Williams, E.R.; Krantz, B.A. Structural basis for the unfolding of anthrax lethal factor by protective antigen oligomers. Nat. Struct. Mol. Biol. 2010, 17, 1383-1390.
47. Christensen, K.A.; Krantz, B.A.; Melnyk, R.A.; Collier, R.J. Interaction of the 20 kDa and 63 kDa fragments of anthrax protective antigen: Kinetics and thermodynamics. Biochemistry 2005, 44, 1047-1053.
48. Kintzer, A.F.; Sterling, H.J.; Tang, I.I.; Abdul-Gader, A.; Miles, A.J.; Wallace, B.A.; Williams, E.R.; Krantz, B.A. Role of the protective antigen octamer in the molecular mechanism of anthrax lethal toxin stabilization in plasma. J. Mol. Biol. 2010, 399, 741-758.
49. Kintzer, A.F.; Sterling, H.J.; Tang, I.I.; Williams, E.R.; Krantz, B.A. Anthrax toxin receptor drives protective antigen oligomerization and stabilizes the heptameric and octameric oligomer by a similar mechanism. PLoS One 2010, 5, e13888.
50. Kintzer, A.F.; Thoren, K.L.; Sterling, H.J.; Dong, K.C.; Feld, G.K.; Tang, I.I.; Zhang, T.T.; Williams, E.R.; Berger, J.M.; Krantz, B.A. The protective antigen component of anthrax toxin forms functional octameric complexes. J. Mol. Biol. 2009, 392, 614-629.
51. Salles, II; Voth, D.E.; Ward, S.C.; Averette, K.M.; Tweten, R.K.; Bradley, K.A.; Ballard, J.D. Cytotoxic activity of Bacillus anthracis protective antigen observed in a macrophage cell line overexpressing ANTXR1. Cell. Microbiol. 2006, 8, 1272-1281.
52. Agrawal, A.; Lingappa, J.; Leppla, S.H.; Agrawal, S.; Jabbar, A.; Quinn, C.; Pulendran, B. Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature 2003, 424, 329-334.
53. Park, J.M.; Greten, F.R.; Li, Z.W.; Karin, M. Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science 2002, 297, 2048-2051.
54. Xu, L.; Frucht, D.M. Bacillus anthracis: A multi-faceted role for anthrax lethal toxin in thwarting host immune defenses. Int. J. Biochem. Cell Biol. 2007, 39, 20-24.
55. Young, J.J.; Bromberg-White, J.L.; Zylstra, C.; Church, J.T.; Boguslawski, E.; Resau, J.H.; Williams, B.O.; Duesbery, N.S. LRP5 and LRP6 are not required for protective antigen-mediated internalization or lethality of anthrax lethal toxin. PLoS Pathog. 2007, 3, e27.
56. Ali, S.R.; Timmer, A.M.; Bilgrami, S.; Park, E.J.; Eckmann, L.; Nizet, V.; Karin, M. Anthrax toxin induces macrophage death by p38 MAPK inhibition but leads to inflammasome activation via ATP leakage. Immunity 2011, 35, 34-44.
57. Cao, S.; Guo, A.; Wu, G.; Liu, Z.; Chen, W.; Feng, C.; Zhang, C.C.; Chen, H. Residue histidine 669 is essential for the catalytic activity of Bacillus anthracis lethal factor. J. Bacteriol. 2010, 192, 5799-5805.
58. Chow, E.M.; Batty, S.; Mogridge, J. Anthrax lethal toxin promotes dephosphorylation of TTP and formation of processing bodies. Cell. Microbiol. 2010, 12, 557-568.
59. Dalkas, G.A.; Chasapis, C.T.; Gkazonis, P.V.; Bentrop, D.; Spyroulias, G.A. Conformational dynamics of the anthrax lethal factor catalytic center. Biochemistry 2010, 49, 10767-10769.
60. Dumas, E.K.; Cox, P.M.; Fullenwider, C.O.; Nguyen, M.; Centola, M.; Frank, M.B.; Dozmorov, I.; James, J.A.; Farris, A.D. Anthrax lethal toxin-induced gene expression changes in mouse lung. Toxins 2011, 3, 1111-1130.
61. Ebrahimi, C.M.; Sheen, T.R.; Renken, C.W.; Gottlieb, R.A.; Doran, K.S. Contribution of lethal toxin and edema toxin to the pathogenesis of anthrax meningitis. Infect. Immun. 2011, 79, 2510-2518.
62. Lee, S.; Wang, Y.; Kim, S.O.; Han, J. AMPD3 is involved in anthrax LeTx-induced macrophage cell death. Protein Cell 2011, 2, 564-572.
63. Liu, T.; Milia, E.; Warburton, R.R.; Hill, N.S.; Gaestel, M.; Kayyali, U.S. Anthrax lethal toxin disrupts the endothelial permeability barrier through blocking p38 signaling. J. Cell. Physiol. 2012, 227, 1438-1445.
64. Sun, C.; Fang, H.; Xie, T.; Auth, R.D.; Patel, N.; Murray, P.R.; Snoy, P.J.; Frucht, D.M. Anthrax lethal toxin disrupts intestinal barrier function and causes systemic infections with enteric bacteria. PLoS One 2012, 7, e33583.
65. Tamayo, A.G.; Slater, L.; Taylor-Parker, J.; Bharti, A.; Harrison, R.; Hung, D.T.; Murphy, J.R. GRP78(BiP) facilitates the cytosolic delivery of anthrax lethal factor (LF) in vivo and functions as an unfoldase in vitro. Mol. Microbiol. 2011, 81, 1390-1401.
66. Thomas, J.; Epshtein, Y.; Chopra, A.; Ordog, B.; Ghassemi, M.; Christman, J.W.; Nattel, S.; Cook, J.L.; Levitan, I. Anthrax lethal factor activates K(+) channels to induce IL-1beta secretion in macrophages. J. Immunol. 2011, 186, 5236-5243.
67. Vuyisich, M.; Sanders, C.K.; Graves, S.W. Binding and cell intoxication studies of anthrax lethal toxin. Mol. Biol. Rep. 2012, 39, 5897-5903.
68. Xie, T.; Auth, R.D.; Frucht, D.M. The effects of anthrax lethal toxin on host barrier function. Toxins 2011, 3, 591-607.
69. Pellizzari, R.; Guidi-Rontani, C.; Vitale, G.; Mock, M.; Montecucco, C. Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNgamma-induced release of NO and TNFalpha. FEBS Lett. 1999, 462, 199-204.
70. Vitale, G.; Bernardi, L.; Napolitani, G.; Mock, M.; Montecucco, C. Susceptibility of mitogenactivated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem. J. 2000, 352 Pt 3, 739-745.
71. Vitale, G.; Pellizzari, R.; Recchi, C.; Napolitani, G.; Mock, M.; Montecucco, C. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem. Biophys. Res. Commun. 1998, 248, 706-711.
72. Vitale, G.; Pellizzari, R.; Recchi, C.; Napolitani, G.; Mock, M.; Montecucco, C. Anthrax lethal factor cleaves the N-terminus of MAPKKS and induces tyrosine/threonine phosphorylation of MAPKS in cultured macrophages. J. Appl. Microbiol. 1999, 87, 288.
73. Ascenzi, P.; Visca, P.; Ippolito, G.; Spallarossa, A.; Bolognesi, M.; Montecucco, C. Anthrax toxin: A tripartite lethal combination. FEBS Lett. 2002, 531, 384-388.
74. Brossier, F.; Mock, M. Toxins of Bacillus anthracis. Toxicon 2001, 39, 1747-1755.
75. Brossier, F.; Weber-Levy, M.; Mock, M.; Sirard, J.C. Role of toxin functional domains in anthrax pathogenesis. Infect. Immun. 2000, 68, 1781-1786.
76. Cunningham, K.; Lacy, D.B.; Mogridge, J.; Collier, R.J. Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen. Proc. Natl. Acad. Sci. USA 2002, 99, 7049-7053.
77. Dal Molin, F.; Tonello, F.; Ladant, D.; Zornetta, I.; Zamparo, I.; Di Benedetto, G.; Zaccolo, M.; Montecucco, C. Cell entry and cAMP imaging of anthrax edema toxin. EMBO J. 2006, 25, 5405-5413.
78. Gnade, B.T.; Moen, S.T.; Chopra, A.K.; Peterson, J.W.; Yeager, L.A. Emergence of anthrax edema toxin as a master manipulator of macrophage and B cell functions. Toxins 2010, 2, 1881-1897.
79. Larabee, J.L.; Maldonado-Arocho, F.J.; Pacheco, S.; France, B.; DeGiusti, K.; Shakir, S.M.; Bradley, K.A.; Ballard, J.D. Glycogen synthase kinase 3 activation is important for anthrax edema toxin-induced dendritic cell maturation and anthrax toxin receptor 2 expression in macrophages. Infect. Immun. 2011, 79, 3302-3308.
80. Szarowicz, S.E.; During, R.L.; Li, W.; Quinn, C.P.; Tang, W.J.; Southwick, F.S. Bacillus anthracis edema toxin impairs neutrophil actin-based motility. Infect. Immun. 2009, 77, 2455-2464.
81. Yeager, L.A.; Chopra, A.K.; Peterson, J.W. Bacillus anthracis edema toxin suppresses human macrophage phagocytosis and cytoskeletal remodeling via the protein kinase A and exchange protein activated by cyclic AMP pathways. Infect. Immun. 2009, 77, 2530-2543.
82. Thoren, K.L.; Krantz, B.A. The unfolding story of anthrax toxin translocation. Mol. Microbiol. 2011, 80, 588-595.
83. Bradley, K.A.; Mogridge, J.; Mourez, M.; Collier, R.J.; Young, J.A. Identification of the cellular receptor for anthrax toxin. Nature 2001, 414, 225-229.
84. Hong, J.; Beeler, J.; Zhukovskaya, N.L.; He, W.; Tang, W.J.; Rosner, M.R. Anthrax edema factor potency depends on mode of cell entry. Biochem. Biophys. Res. Commun. 2005, 335, 850-857.
85. Hong, J.; Doebele, R.C.; Lingen, M.W.; Quilliam, L.A.; Tang, W.J.; Rosner, M.R. Anthrax edema toxin inhibits endothelial cell chemotaxis via Epac and Rap1. J. Biol. Chem. 2007, 282, 19781-19787.
86. Liu, S.; Leppla, S.H. Cell surface tumor endothelium marker 8 cytoplasmic tail-independent anthrax toxin binding, proteolytic processing, oligomer formation, and internalization. J. Biol. Chem. 2003, 278, 5227-5234.
87. Santelli, E.; Bankston, L.A.; Leppla, S.H.; Liddington, R.C. Crystal structure of a complex between anthrax toxin and its host cell receptor. Nature 2004, 430, 905-908.
88. Scobie, H.M.; Marlett, J.M.; Rainey, G.J.; Lacy, D.B.; Collier, R.J.; Young, J.A. Anthrax toxin receptor 2 determinants that dictate the pH threshold of toxin pore formation. PLoS One 2007, 2, e329.
89. Scobie, H.M.; Rainey, G.J.; Bradley, K.A.; Young, J.A. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc. Natl. Acad. Sci. USA 2003, 100, 5170-5174.
90. Bell, S.E.; Mavila, A.; Salazar, R.; Bayless, K.J.; Kanagala, S.; Maxwell, S.A.; Davis, G.E. Differential gene expression during capillary morphogenesis in 3D collagen matrices: Regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. J. Cell Sci. 2001, 114, 2755-2773.
91. Carson-Walter, E.B.; Watkins, D.N.; Nanda, A.; Vogelstein, B.; Kinzler, K.W.; St Croix, B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res. 2001, 61, 6649-6655.
92. Deuquet, J.; Lausch, E.; Superti-Furga, A.; van der Goot, F.G. The dark sides of capillary morphogenesis gene 2. EMBO J 2012, 31, 3-13.
93. Fu, S.; Tong, X.; Cai, C.; Zhao, Y.; Wu, Y.; Li, Y.; Xu, J.; Zhang, X.C.; Xu, L.; Chen, W.; et al. The structure of tumor endothelial marker 8 (TEM8) extracellular domain and implications for its receptor function for recognizing anthrax toxin. PLoS One 2010, 5, e11203.
94. Klimpel, K.R.; Molloy, S.S.; Thomas, G.; Leppla, S.H. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc. Natl. Acad. Sci. USA 1992, 89, 10277-10281.
95. Milne, J.C.; Furlong, D.; Hanna, P.C.; Wall, J.S.; Collier, R.J. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J. Biol. Chem. 1994, 269, 20607-20612.
96. Petosa, C.; Collier, R.J.; Klimpel, K.R.; Leppla, S.H.; Liddington, R.C. Crystal structure of the anthrax toxin protective antigen. Nature 1997, 385, 833-838.
97. Abrami, L.; Liu, S.; Cosson, P.; Leppla, S.H.; van der Goot, F.G. Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J. Cell Biol. 2003, 160, 321-328.
98. Christensen, K.A.; Krantz, B.A.; Collier, R.J. Assembly and disassembly kinetics of anthrax toxin complexes. Biochemistry 2006, 45, 2380-2386.
99. Gordon, V.M.; Leppla, S.H.; Hewlett, E.L. Inhibitors of receptor-mediated endocytosis block the entry of Bacillus anthracis adenylate cyclase toxin but not that of Bordetella pertussis adenylate cyclase toxin. Infect. Immun. 1988, 56, 1066-1069.
100. Mogridge, J.; Cunningham, K.; Lacy, D.B.; Mourez, M.; Collier, R.J. The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen. Proc. Natl. Acad. Sci. USA 2002, 99, 7045-7048.
101. Mogridge, J.; Cunningham, K.; Collier, R.J. Stoichiometry of anthrax toxin complexes. Biochemistry 2002, 41, 1079-1082.
102. Benson, E.L.; Huynh, P.D.; Finkelstein, A.; Collier, R.J. Identification of residues lining the anthrax protective antigen channel. Biochemistry 1998, 37, 3941-3948.
103. Friedlander, A.M. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J. Biol. Chem. 1986, 261, 7123-7126.
104. Paccani, S.R.; Baldari, C.T. T cell targeting by anthrax toxins: Two faces of the same coin. Toxins 2011, 3, 660-671.
105. Janowiak, B.E.; Jennings-Antipov, L.D.; Collier, R.J. Cys-Cys cross-linking shows contact between the N-terminus of lethal factor and Phe427 of the anthrax toxin pore. Biochemistry 2011, 50, 3512-3516.
106. Katayama, H.; Janowiak, B.E.; Brzozowski, M.; Juryck, J.; Falke, S.; Gogol, E.P.; Collier, R.J.; Fisher, M.T. GroEL as a molecular scaffold for structural analysis of the anthrax toxin pore. Nat. Struct. Mol. Biol. 2008, 15, 754-760.
107. Katayama, H.; Wang, J.; Tama, F.; Chollet, L.; Gogol, E.P.; Collier, R.J.; Fisher, M.T. Three-dimensional structure of the anthrax toxin pore inserted into lipid nanodiscs and lipid vesicles. Proc. Natl. Acad. Sci. USA 2010, 107, 3453-3457.
108. Pilpa, R.M.; Bayrhuber, M.; Marlett, J.M.; Riek, R.; Young, J.A. A receptor-based switch that regulates anthrax toxin pore formation. PLoS Pathog. 2011, 7, e1002354.
109. Brown, M.J.; Thoren, K.L.; Krantz, B.A. Charge requirements for proton gradient-driven translocation of anthrax toxin. J. Biol. Chem. 2011, 286, 23189-23199.
110. Basilio, D.; Kienker, P.K.; Briggs, S.W.; Finkelstein, A. A kinetic analysis of protein transport through the anthrax toxin channel. J. Gen. Physiol. 2011, 137, 521-531.
111. Duesbery, N.S.; Webb, C.P.; Leppla, S.H.; Gordon, V.M.; Klimpel, K.R.; Copeland, T.D.; Ahn, N.G.; Oskarsson, M.K.; Fukasawa, K.; Paull, K.D.; et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998, 280, 734-737.
112. Baldari, C.T.; Tonello, F.; Paccani, S.R.; Montecucco, C. Anthrax toxins: A paradigm of bacterial immune suppression. Trends Immunol. 2006, 27, 434-440.
113. Rossi Paccani, S.; Tonello, F.; Patrussi, L.; Capitani, N.; Simonato, M.; Montecucco, C.; Baldari, C.T. Anthrax toxins inhibit immune cell chemotaxis by perturbing chemokine receptor signalling. Cell. Microbiol. 2007, 9, 924-929.
114. Kirby, J.E. Anthrax lethal toxin induces human endothelial cell apoptosis. Infect. Immun. 2004, 72, 430-439.
115. Laine, E.; Martinez, L.; Blondel, A.; Malliavin, T.E. Activation of the edema factor of Bacillus anthracis by calmodulin: Evidence of an interplay between the EF-calmodulin interaction and calcium binding. Biophys. J 2010, 99, 2264-2272.
116. Dal Molin, F.; Zornetta, I.; Puhar, A.; Tonello, F.; Zaccolo, M.; Montecucco, C. cAMP imaging of cells treated with pertussis toxin, cholera toxin, and anthrax edema toxin. Biochem. Biophys. Res. Commun. 2008, 376, 429-433.
117. Pezard, C.; Berche, P.; Mock, M. Contribution of individual toxin components to virulence of Bacillus anthracis. Infect. Immun. 1991, 59, 3472-3477.
118. Stanley, J.L.; Smith, H. Purification of factor 1 and recognition of a third factor of the anthrax toxin. J. Gen. Microbiol. 1961, 26, 49-63.
119. Lovchik, J.A.; Drysdale, M.; Koehler, T.M.; Hutt, J.A.; Lyons, C.R. Expression of either Lethal Toxin or Edema Toxin by Bacillus anthracis is Sufficient for Virulence in a Rabbit Model of Inhalational Anthrax. Infect. Immun. 2012, doi: 10.1128/IAI.06340-11.
120. Confer, D.L.; Eaton, J.W. Phagocyte impotence caused by an invasive bacterial adenylate cyclase. Science 1982, 217, 948-950.
121. Leppla, S.H. Anthrax toxin edema factor: A bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. USA 1982, 79, 3162-3166.
122. Leppla, S.H. Purification and characterization of adenylyl cyclase from Bacillus anthracis. Methods Enzymol. 1991, 195, 153-168.
123. ÓBrien, J.; Friedlander, A.; Dreier, T.; Ezzell, J.; Leppla, S. Effects of anthrax toxin components on human neutrophils. Infect. Immun. 1985, 47, 306-310.
124. Tournier, J.N.; Quesnel-Hellmann, A.; Mathieu, J.; Montecucco, C.; Tang, W.J.; Mock, M.; Vidal, D.R.; Goossens, P.L. Anthrax edema toxin cooperates with lethal toxin to impair cytokine secretion during infection of dendritic cells. J. Immunol. 2005, 174, 4934-4941.
125. Crawford, M.A.; Aylott, C.V.; Bourdeau, R.W.; Bokoch, G.M. Bacillus anthracis toxins inhibit human neutrophil NADPH oxidase activity. J. Immunol. 2006, 176, 7557-7565.
126. Larabee, J.L.; Shakir, S.M.; Hightower, L.; Ballard, J.D. Adenomatous polyposis coli protein associates with C/EBP beta and increases Bacillus anthracis edema toxin-stimulated gene expression in macrophages. J. Biol. Chem. 2011, 286, 19364-19372.
127. Voth, D.E.; Hamm, E.E.; Nguyen, L.G.; Tucker, A.E.; Salles, I.I.; Ortiz-Leduc, W.; Ballard, J.D. Bacillus anthracis oedema toxin as a cause of tissue necrosis and cell type-specific cytotoxicity. Cell. Microbiol. 2005, 7, 1139-1149.
128. Paccani, S.R.; Tonello, F.; Ghittoni, R.; Natale, M.; Muraro, L.; D́Elios, M.M.; Tang, W.J.; Montecucco, C.; Baldari, C.T. Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling. J. Exp. Med. 2005, 201, 325-331.
129. Puhar, A.; Dal Molin, F.; Horvath, S.; Ladant, D.; Montecucco, C. Anthrax edema toxin modulates PKA-and CREB-dependent signaling in two phases. PLoS One 2008, 3, e3564.
130. Firoved, A.M.; Moayeri, M.; Wiggins, J.F.; Shen, Y.; Tang, W.J.; Leppla, S.H. Anthrax edema toxin sensitizes DBA/2J mice to lethal toxin. Infect. Immun. 2007, 75, 2120-2125.
131. Hicks, C.W.; Cui, X.; Sweeney, D.A.; Li, Y.; Barochia, A.; Eichacker, P.Q. The potential contributions of lethal and edema toxins to the pathogenesis of anthrax associated shock. Toxins 2011, 3, 1185-1202.
132. Dumetz, F.; Jouvion, G.; Khun, H.; Glomski, I.J.; Corre, J.P.; Rougeaux, C.; Tang, W.J.; Mock, M.; Huerre, M.; Goossens, P.L. Noninvasive imaging technologies reveal edema toxin as a key virulence factor in anthrax. Am. J. Pathol. 2011, 178, 2523-2535.
133. Brey, R.N. Molecular basis for improved anthrax vaccines. Adv. Drug Deliv. Rev. 2005, 57, 1266-1292.
134. Scorpio, A.; Blank, T.E.; Day, W.A.; Chabot, D.J. Anthrax vaccines: Pasteur to the present. Cell. Mol. Life Sci. 2006, 63, 2237-2248.
135. Scorpio, A.; Chabot, D.J.; Day, W.A.; ÓBrien, D.K.; Vietri, N.J.; Itoh, Y.; Mohamadzadeh, M.; Friedlander, A.M. Poly-γ-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis. Antimicrob. Agents. Chemother. 2007, 51, 215-222.
136. Tournier, J.N.; Ulrich, R.G.; Quesnel-Hellmann, A.; Mohamadzadeh, M.; Stiles, B.G. Anthrax, toxins and vaccines: A 125-year journey targeting Bacillus anthracis. Expert Rev. Anti Infect. Ther. 2009, 7, 219-236.
137. Riddle, V.; Leese, P.; Blanset, D.; Adamcio, M.; Meldorf, M.; Lowy, I. Phase I study evaluating the safety and pharmacokinetics of MDX-1303, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin. Vaccine Immunol. 2011, 18, 2136-2142.
138. Little, S.F.; Webster, W.M.; Fisher, D.E. Monoclonal antibodies directed against protective antigen of Bacillus anthracis enhance lethal toxin activity in vivo. FEMS Immunol. Med. Microbiol. 2011, 62, 11-22.
139. vor dem Esche, U.; Huber, M.; Zgaga-Griesz, A.; Grunow, R.; Beyer, W.; Hahn, U.; Bessler, W.G. Passive vaccination with a human monoclonal antibody: Generation of antibodies and studies for efficacy in Bacillus anthracis infections. Immunobiology 2011, 216, 847-853.
140. Chitlaru, T.; Altboum, Z.; Reuveny, S.; Shafferman, A. Progress and novel strategies in vaccine development and treatment of anthrax. Immunol. Rev. 2011, 239, 221-236.
141. Altaweel, L.; Chen, Z.; Moayeri, M.; Cui, X.; Li, Y.; Su, J.; Fitz, Y.; Johnson, S.; Leppla, S.H.; Purcell, R.; et al. Delayed treatment with W1-mAb, a chimpanzee-derived monoclonal antibody against protective antigen, reduces mortality from challenges with anthrax edema or lethal toxin in rats and with anthrax spores in mice. Crit. Care Med. 2011, 39, 1439-1447.
142. Makiya, M.; Dolan, M.; Agulto, L.; Purcell, R.; Chen, Z. Structural basis of anthrax edema factor neutralization by a neutralizing antibody. Biochem. Biophys. Res. Commun. 2012, 417, 324-329.
143. Leysath, C.E.; Chen, K.H.; Moayeri, M.; Crown, D.; Fattah, R.; Chen, Z.; Das, S.R.; Purcell, R.H.; Leppla, S.H. Mouse monoclonal antibodies to anthrax edema factor protect against infection. Infect. Immun. 2011, 79, 4609-4616.
144. Chen, Z.; Moayeri, M.; Purcell, R. Monoclonal Antibody Therapies against Anthrax. Toxins 2011, 3, 1004-1019.
145. Crowe, S.R.; Garman, L.; Engler, R.J.; Farris, A.D.; Ballard, J.D.; Harley, J.B.; James, J.A. Anthrax vaccination induced anti-lethal factor IgG: Fine specificity and neutralizing capacity. Vaccine 2011, 29, 3670-3678.
146. Kulshreshtha, P.; Bhatnagar, R. Inhibition of anthrax toxins with a bispecific monoclonal antibody that cross reacts with edema factor as well as lethal factor of Bacillus anthracis. Mol. Immunol. 2011, 48, 1958-1965.
147. Pini, A.; Runci, Y.; Falciani, C.; Lelli, B.; Brunetti, J.; Pileri, S.; Fabbrini, M.; Lozzi, L.; Ricci, C.; Bernini, A. et al. Stable peptide inhibitors prevent binding of lethal and oedema factors to protective antigen and neutralize anthrax toxin in vivo. Biochem. J. 2006, 395, 157-163.
148. Laine, E.; Goncalves, C.; Karst, J.C.; Lesnard, A.; Rault, S.; Tang, W.J.; Malliavin, T.E.; Ladant, D.; Blondel, A. Use of allostery to identify inhibitors of calmodulin-induced activation of Bacillus anthracis edema factor. Proc. Natl. Acad. Sci. USA 2010, 107, 11277-11282.
149. Dessauer, C.W.; Tesmer, J.J.; Sprang, S.R.; Gilman, A.G. The interactions of adenylate cyclases with P-site inhibitors. Trends Pharmacol. Sci. 1999, 20, 205-210.
150. Tesmer, J.J.; Dessauer, C.W.; Sunahara, R.K.; Murray, L.D.; Johnson, R.A.; Gilman, A.G.; Sprang, S.R. Molecular basis for P-site inhibition of adenylyl cyclase. Biochemistry 2000, 39, 14464-14471.
151. Johnson, R.A.; Shoshani, I. Inhibition of Bordetella pertussis and Bacillus anthracis adenylyl cyclases by polyadenylate and "P"-site agonists. J. Biol. Chem. 1990, 265, 19035-19039.
152. Shen, Y.; Zhukovskaya, N.L.; Zimmer, M.I.; Soelaiman, S.; Bergson, P.; Wang, C.R.; Gibbs, C.S.; Tang, W.J. Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 2004, 101, 3242-3247.
153. Soelaiman, S.; Wei, B.Q.; Bergson, P.; Lee, Y.S.; Shen, Y.; Mrksich, M.; Shoichet, B.K.; Tang, W.J. Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J. Biol. Chem. 2003, 278, 25990-25997.
154. Lee, Y.S.; Bergson, P.; He, W.S.; Mrksich, M.; Tang, W.J. Discovery of a small molecule that inhibits the interaction of anthrax edema factor with its cellular activator, calmodulin. Chem. Biol. 2004, 11, 1139-1146.
155. Gille, A.; Seifert, R. MANT-substituted guanine nucleotides: A novel class of potent adenylyl cyclase inhibitors. Life Sci. 2003, 74, 271-279.
156. Gille, A.; Seifert, R. 2′(3′)-O-(N-methylanthraniloyl)-substituted GTP analogs: A novel class of potent competitive adenylyl cyclase inhibitors. J. Biol. Chem. 2003, 278, 12672-12679.
157. Taha, H.; Dove, S.; Geduhn, J.; König, B.; Shen, Y.; Tang, W.J.; Seifert, R. Inhibition of the adenylyl cyclase toxin, edema factor, from Bacillus anthracis by a series of 18 mono-and bis-(M)ANT-substituted nucleoside 5′-triphosphates. Naunyn Schmiedebergs Arch. Pharmacol. 2012, 385, 57-68.
158. Taha, H.M.; Schmidt, J.; Göttle, M.; Suryanarayana, S.; Shen, Y.; Tang, W.J.; Gille, A.; Geduhn, J.; König, B.; Dove, S.; et al. Molecular analysis of the interaction of anthrax adenylyl cyclase toxin, edema factor, with 2′(3′)-O-(N-(methyl)anthraniloyl)-substituted purine and pyrimidine nucleotides. Mol. Pharmacol. 2009, 75, 693-703.
159. Gille, A.; Lushington, G.H.; Mou, T.C.; Doughty, M.B.; Johnson, R.A.; Seifert, R. Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides. J. Biol. Chem. 2004, 279, 19955-19969.
160. Geduhn, J.; Dove, S.; Shen, Y.; Tang, W.J.; König, B.; Seifert, R. Bis-halogen-anthraniloylsubstituted nucleoside 5′-triphosphates as potent and selective inhibitors of Bordetella pertussis adenylyl cyclase toxin. J. Pharmacol. Exp. Ther. 2011, 336, 104-115.
161. Gaion, R.M.; Krishna, G. Cytidylate cyclase: Possible artifacts in the methodology. Science 1979, 203, 672-673.
162. Gaion, R.M.; Krishna, G. Cytidylate cyclase: The product isolated by the method of Cech and Ignarro is not cytidine 3′,5′-monophosphate. Biochem. Biophys. Res. Commun. 1979, 86, 105-111.
163. Göttle, M.; Dove, S.; Kees, F.; Schlossmann, J.; Geduhn, J.; König, B.; Shen, Y.; Tang, W.J.; Kaever, V.; Seifert, R. Cytidylyl and uridylyl cyclase activity of Bacillus anthracis edema factor and Bordetella pertussis CyaA. Biochemistry 2010, 49, 5494-5503.
164. Flynn, G.E.; Zagotta, W.N. A cysteine scan of the inner vestibule of cyclic nucleotide-gated channels reveals architecture and rearrangement of the pore. J. Gen. Physiol. 2003, 121, 563-582.
165. Sunderman, E.R.; Zagotta, W.N. Sequence of events underlying the allosteric transition of rod cyclic nucleotide-gated channels. J. Gen. Physiol. 1999, 113, 621-640.
166. Sunderman, E.R.; Zagotta, W.N. Mechanism of allosteric modulation of rod cyclic nucleotide-gated channels. J. Gen. Physiol. 1999, 113, 601-620.
167. Postea, O.; Biel, M. Exploring HCN channels as novel drug targets. Nat. Rev. Drug Discov. 2011, 10, 903-914.
168. Bush, L.M.; Abrams, B.H.; Beall, A.; Johnson, C.C. Index case of fatal inhalational anthrax due to bioterrorism in the United States. N. Engl. J. Med. 2001, 345, 1607-1610.
169. Jernigan, J.A.; Stephens, D.S.; Ashford, D.A.; Omenaca, C.; Topiel, M.S.; Galbraith, M.; Tapper, M.; Fisk, T.L.; Zaki, S.; Popovic, T.; et al. Bioterrorism-related inhalational anthrax: The first 10 cases reported in the United States. Emerg. Infect. Dis. 2001, 7, 933-944.
170. Guarner, J.; Jernigan, J.A.; Shieh, W.J.; Tatti, K.; Flannagan, L.M.; Stephens, D.S.; Popovic, T.; Ashford, D.A.; Perkins, B.A.; Zaki, S.R. Pathology and pathogenesis of bioterrorism-related inhalational anthrax. Am. J. Pathol. 2003, 163, 701-709.
171. Nguyen, C.; Feng, C.; Zhan, M.; Cross, A.S.; Goldblum, S.E. Bacillus anthracis-derived edema toxin (ET) counter-regulates movement of neutrophils and macromolecules through the endothelial paracellular pathway. BMC Microbiol. 2012, 12, 2.
172. Twenhafel, N.A.; Leffel, E.; Pitt, M.L. Pathology of inhalational anthrax infection in the african green monkey. Vet. Pathol. 2007, 44, 716-721.
173. He, P.; Zeng, M.; Curry, F.E. Dominant role of cAMP in regulation of microvessel permeability. Am. J. Physiol. Heart Circ. Physiol. 2000, 278, H1124-1133.
174. Waschke, J.; Drenckhahn, D.; Adamson, R.H.; Barth, H.; Curry, F.E. cAMP protects endothelial barrier functions by preventing Rac-1 inhibition. Am. J. Physiol. Heart Circ. Physiol. 2004, 287, H2427-2433.
175. Fukuhara, S.; Sakurai, A.; Sano, H.; Yamagishi, A.; Somekawa, S.; Takakura, N.; Saito, Y.; Kangawa, K.; Mochizuki, N. Cyclic AMP potentiates vascular endothelial cadherin-mediated cell-cell contact to enhance endothelial barrier function through an Epac-Rap1 signaling pathway. Mol. Cell. Biol. 2005, 25, 136-146.
176. Drum, C.L.; Yan, S.Z.; Bard, J.; Shen, Y.Q.; Lu, D.; Soelaiman, S.; Grabarek, Z.; Bohm, A.; Tang, W.J. Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature 2002, 415, 396-402.
177. Shen, Y.; Zhukovskaya, N.L.; Guo, Q.; Florian, J.; Tang, W.J. Calcium-independent calmodulin binding and two-metal-ion catalytic mechanism of anthrax edema factor. EMBO J 2005, 24, 929-941.
178. Guo, Q.; Shen, Y.; Lee, Y.S.; Gibbs, C.S.; Mrksich, M.; Tang, W.J. Structural basis for the interaction of Bordetella pertussis adenylyl cyclase toxin with calmodulin. EMBO J. 2005, 24, 3190-3201.
179. Zea, C.J.; Camci-Unal, G.; Pohl, N.L. Thermodynamics of binding of divalent magnesium and manganese to uridine phosphates: Implications for diabetes-related hypomagnesaemia and carbohydrate biocatalysis. Chem. Cent. J. 2008, 2, 15.
180. Bock, C.W.; Kaufman Katz, A.; Markham, G.D.; Glusker, J.P. Manganese as a Replacement for Magnesium and Zinc:_ Functional Comparison of the Divalent Ions. J. Am. Chem. Soc. 1999, 121, 7360-7372.
181. Newton, R.P.; Salih, S.G.; Salvage, B.J.; Kingston, E.E. Extraction, purification and identification of cytidine 3′,5′-cyclic monophosphate from rat tissues. Biochem. J. 1984, 221, 665-673.
182. Newton, R.P.; Salvage, B.J.; Hakeem, N.A. Cytidylate cyclase: Development of assay and determination of kinetic properties of a cytidine 3′,5′-cyclic monophosphate-synthesizing enzyme. Biochem. J. 1990, 265, 581-586.
183. Newton, R.P.; Groot, N.; van Geyschem, J.; Diffley, P.E.; Walton, T.J.; Bayliss, M.A.; Harris, F.M.; Games, D.E.; Brenton, A.G. Estimation of cytidylyl cyclase activity and monitoring of side-product formation by fast-atom bombardment mass spectrometry. Rapid Commun. Mass Spectrom. 1997, 11, 189-194.
184. Newton, R.P.; Evans, A.M.; van Geyschem, J.; Diffley, P.J.; Hassam, H.G.; Hakeem, N.A.; Moyse, C.D.; Cooke, R.; Salvage, B.J. Radioimmunoassay of cytidine 3′,5′-cyclic monophosphate: Unambiguous assay by means of an optimized protocol incorporating a trilayer column separation to obviate cross-reactivity problems. J. Immunoassay 1994, 15, 317-337.
185. Newton, R.P.; Kingston, E.E.; Hakeem, N.A.; Salih, S.G.; Beynon, J.H.; Moyse, C.D. Extraction, purification, identification and metabolism of 3′,5′-cyclic UMP, 3′,5′-cyclic IMP and 3′,5′-cyclic dTMP from rat tissues. Biochem. J. 1986, 236, 431-439.
186. Elliott, G.R.; Lauwen, A.P.; Bonta, I.L. Dibutyryl cytidine 3′:5′-cyclic monophosphate; an inhibitor of A23187-stimulated macrophage leukotriene B4 synthesis. Agents Actions 1991, 32, 90-91.
187. Ervens, J.; Seifert, R. Differential modulation by N4,2′-O-dibutyryl cytidine 3′:5′-cyclic monophosphate of neutrophil activation. Biochem. Biophys. Res. Commun. 1991, 174, 258-267.
188. Burhenne, H.; Beste, K.Y.; Spangler, C.M.; Voigt, U.; Kaever, V.; Seifert, R. Determination of cytidine 3′,5′-cyclic monophosphate and uridine 3′,5′-cyclic monophosphate in mammalian cell systems and in human urine by highperformance liquid chromatography/mass spectrometry. Naunyn-Schmiedeberg's Arch. Pharmacol. 2011, 383 (Suppl. 1), P096.
189. Taylor, S.S.; Kim, C.; Cheng, C.Y.; Brown, S.H.; Wu, J.; Kannan, N. Signaling through cAMP and cAMP-dependent protein kinase: Diverse strategies for drug design. Biochim. Biophys. Acta 2008, 1784, 16-26.
190. Kim, C.; Cheng, C.Y.; Saldanha, S.A.; Taylor, S.S. PKA-I holoenzyme structure reveals a mechanism for cAMP-dependent activation. Cell 2007, 130, 1032-1043.
191. Taylor, S.S.; Kim, C.; Vigil, D.; Haste, N.M.; Yang, J.; Wu, J.; Anand, G.S. Dynamics of signaling by PKA. Biochim. Biophys. Acta 2005, 1754, 25-37.
192. Casteel, D.E.; Smith-Nguyen, E.V.; Sankaran, B.; Roh, S.H.; Pilz, R.B.; Kim, C. A crystal structure of the cyclic GMP-dependent protein kinase I{beta} dimerization/docking domain reveals molecular details of isoform-specific anchoring. J. Biol. Chem. 2010, 285, 32684-32688.
193. Desch, M.; Schinner, E.; Kees, F.; Hofmann, F.; Seifert, R.; Schlossmann, J. Cyclic cytidine 3′,5′-monophosphate (cCMP) signals via cGMP kinase I. FEBS Lett. 2010, 584, 3979-3984.
194. Wolter, S.; Golombek, M.; Seifert, R. Differential activation of cAMP-and cGMP-dependent protein kinases by cyclic purine and pyrimidine nucleotides. Biochem. Biophys. Res. Commun. 2011, 415, 563-566.
195. Newton, R.P.; Khan, J.A.; Brenton, A.G.; Langridge, J.I.; Harris, F.M.; Walton, T.J. Quantitation by fast-atom bombardment mass spectrometry: Assay of cytidine 3′,5′-cyclic monophosphateresponsive protein kinase. Rapid Commun. Mass Spectrom. 1992, 6, 601-607.
196. Bond, A.E.; Dudley, E.; Tuytten, R.; Lemiere, F.; Smith, C.J.; Esmans, E.L.; Newton, R.P. Mass spectrometric identification of Rab23 phosphorylation as a response to challenge by cytidine 3′,5′-cyclic monophosphate in mouse brain. Rapid Commun. Mass Spectrom. 2007, 21, 2685-2692.
197. Ding, S.; Bond, A.E.; Lemiere, F.; Tuytten, R.; Esmans, E.L.; Brenton, A.G.; Dudley, E.; Newton, R.P. Online immobilized metal affinity chromatography/mass spectrometric analysis of changes elicited by cCMP in the murine brain phosphoproteome. Rapid Commun. Mass Spectrom. 2008, 22, 4129-4138.
198. Hammerschmidt, A.; Chatterji, B.; Zeiser, J.; Schröder, A.; Genieser, H.G.; Pich, A.; Kaever, V.; Schwede, F.; Wolter, S.; Seifert, R. Binding of regulatory subunits of cyclic AMP-dependent protein kinase to cyclic CMP agarose. PLoS One 2012, accepted for publication, PONE-D-12-13426 10.1371/journal. pone.0039848.
199. Reinecke, D.; Burhenne, H.; Sandner, P.; Kaever, V.; Seifert, R. Human cyclic nucleotide phosphodiesterases possess a much broader substrate-specificity than previously appreciated. FEBS Lett. 2011, 585, 3259-3262.
200. Bender, A.T.; Beavo, J.A. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol. Rev. 2006, 58, 488-520.
201. Conti, M.; Beavo, J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 2007, 76, 481-511.
202. Helfman, D.M.; Katoh, N.; Kuo, J.F. Purification and properties of cyclic CMP phosphodiesterase. Adv. Cyclic Nucleotide Protein Phosphorylation Res. 1984, 16, 403-416.
203. Newton, R.P.; Salih, S.G. Cyclic CMP phosphodiesterase: Isolation, specificity and kinetic properties. Int. J. Biochem. 1986, 18, 743-752.
204. Newton, R.P.; Bayliss, M.A.; Khan, J.A.; Bastani, A.; Wilkins, A.C.; Games, D.E.; Walton, T.J.; Brenton, A.G.; Harris, F.M. Kinetic analysis of cyclic CMP-specific and multifunctional phosphodiesterases by quantitative positive-ion fast-atom bombardment mass spectrometry. Rapid Commun. Mass Spectrom. 1999, 13, 574-584.
205. Biel, M. Cyclic nucleotide-regulated cation channels. J. Biol. Chem. 2009, 284, 9017-9021.
206. Kaupp, U.B.; Niidome, T.; Tanabe, T.; Terada, S.; Bonigk, W.; Stuhmer, W.; Cook, N.J.; Kangawa, K.; Matsuo, H.; Hirose, T.; et al. Primary structure and functional expression from complementary DNA of the rod photoreceptor cyclic GMP-gated channel. Nature 1989, 342, 762-766.
207. Contreras, J.E.; Holmgren, M. Access of quaternary ammonium blockers to the internal pore of cyclic nucleotide-gated channels: Implications for the location of the gate. J. Gen. Physiol. 2006, 127, 481-494.
208. Varnum, M.D.; Black, K.D.; Zagotta, W.N. Molecular mechanism for ligand discrimination of cyclic nucleotide-gated channels. Neuron 1995, 15, 619-625.
209. Shapiro, M.S.; Zagotta, W.N. Structural basis for ligand selectivity of heteromeric olfactory cyclic nucleotide-gated channels. Biophys. J. 2000, 78, 2307-2320.
210. Zong, X.; Krause, S.; Chen, C.C.; Gruner, C.; Cao-Ehlker, X.; Fenske, S.; Wahl-Schott, C.; Biel, M. Regulation of HCN channel activity by Cyclic Cytidine 3′,5′-Monophosphate. Naunyn-Schmiedeberǵs Arch. Pharmacol. 2012, 385, S1-S116.
211. Beste, K.Y.; Burhenne, H.; Kaever, V.; Stasch, J.P.; Seifert, R. Nucleotidyl cyclase activity of soluble guanylyl cyclase alpha1beta1. Biochemistry 2012, 51, 194-204.